Unknown

Dataset Information

0

Do we really know who has an MGMT methylated glioma? Results of an international survey regarding use of MGMT analyses for glioma.


ABSTRACT: Background:Glioma O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status informs clinical decision making. Worldwide different methods and cutoff levels are used, which can lead to discordant methylation results. Methods:We conducted an international survey to clarify which methods are regularly used and why. We also explored opinions regarding international consensus on methods and cutoff. Results:The survey had 152 respondents from 25 countries. MGMT methylation status is determined for all glioblastomas in 37% of laboratories. The most common methods are methylation-specific polymerase chain reaction (msPCR) (37%) and pyrosequencing (34%). A method is selected for simplicity (56%), cost-effectiveness (50%), and reproducibility of results (52%). For sequencing, the number of CpG sites analyzed varies from 1-3 up to more than 16. For 50% of laboratories, the company producing the kit determines which CpG sites are examined, whereas 33% select the sites themselves. Selection of cutoff is equally distributed among a cutoff defined in the literature, by the local laboratory, or by the outside laboratory performing the analysis. This cutoff varies, reported from 1% to 30%, and in 1 laboratory tumor is determined as methylated in case of 1 methylated CpG site of 17 analyzed. Some report tumors as unmethylated or weakly vs highly methylated. An international consensus on MGMT methylation method and cutoff is warranted by 66% and 76% of respondents, respectively. The method preferred would be msPCR (45%) or pyrosequencing (42%), whereas 18% suggest next-generation sequencing. Conclusion:Although analysis of MGMT methylation status is routine, there is controversy regarding laboratory methods and cutoff level. Most respondents favor development of international consensus guidelines.

SUBMITTER: Malmstrom A 

PROVIDER: S-EPMC6993038 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Do we really know who has an <i>MGMT</i> methylated glioma? Results of an international survey regarding use of <i>MGMT</i> analyses for glioma.

Malmström Annika A   Łysiak Małgorzata M   Kristensen Bjarne Winther BW   Hovey Elizabeth E   Henriksson Roger R   Söderkvist Peter P  

Neuro-oncology practice 20190924 1


<h4>Background</h4>Glioma O6-methylguanine-DNA methyltransferase (<i>MGMT</i>) promoter methylation status informs clinical decision making. Worldwide different methods and cutoff levels are used, which can lead to discordant methylation results.<h4>Methods</h4>We conducted an international survey to clarify which methods are regularly used and why. We also explored opinions regarding international consensus on methods and cutoff.<h4>Results</h4>The survey had 152 respondents from 25 countries.  ...[more]

Similar Datasets

| S-EPMC5409217 | biostudies-literature
| S-EPMC7232918 | biostudies-literature
| S-EPMC8280043 | biostudies-literature
| S-EPMC5626028 | biostudies-literature
| S-EPMC5643071 | biostudies-literature
| S-EPMC8204407 | biostudies-literature
| S-EPMC3441934 | biostudies-literature
| S-EPMC5060931 | biostudies-literature
| S-EPMC4799684 | biostudies-literature
| S-EPMC4921483 | biostudies-other